🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Eisai to divest China rights for Pariet, a proton-pump inhibitor, to CBC Group-controlled Peak Pharma Eisai will receive RMB725 million as contractual upfront payments, as well as the rights to receive a sales milestone payment eisai.com/news/2025/news…

This is going to be an absolutely huge deal in the biotech sector, where Marks was seen as somebody pushing for new therapies and tech, and trying to get products to market to help patients.

Massive development: FDA's Peter Marks resigns endpts.com/fdas-peter-mar…

New: At least seven people have died in the US from symptoms linked to a new Alzheimer's drug over the past two years. Regulators and doctors are divided over the risks. Story w/ Robert Langreth bloomberg.com/news/features/…

big year ahead for Summit Tx partner Akeso: Chinese Biotech Eyes US Nod for Cancer Therapy Eluding Merck bloomberg.com/news/articles/… via Bloomberg

Chinese brain chip project speeds up human trials after first success This follows a move this month by the Nation Healthcare Security Administration to create reimbursement pathways for brain-computer interface, another sign of strong gov support reuters.com/business/healt…

In our interview, Akeso CEO Michelle Xia compared its PD-1/VEGF bispecific to a smartphone with a camera - versus previous approaches akin to carrying a cell phone in one pocket and a camera in the other. That “opens the user to a very different set of opportunities," she said.

Novo Holdings Wants to Do More China Biotech Deals, CEO Says bloomberg.com/news/articles/… via Bloomberg

Lilly CEO Dave Ricks spoke with ⁦BBC⁩ about tariffs: “We cant breach those agreements so we have to eat the cost of the tariffs … Typically that will be in reduction of staff or research and development and I predict R&D will come first.” bbc.com/news/articles/…

wow - Charles Lieber, the retired Harvard University chemist convicted in 2021 for not disclosing his China ties, joined Tsinghua University as a chair professor scmp.com/news/china/sci…

China's push to build a Great Green Wall has spurred more hay fever cases. Here's what its governments are doing to combat this. bloomberg.com/news/newslette…

Roche will invest 2.04 billion yuan ($282 million) to launch a new site in Shanghai for the localized production of biologic drugs, starting with Vabysmo. chinadaily.com.cn/a/202505/09/WS…

Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion PD-1/VEGF deal alert: bloomberg.com/news/articles/…

Top Chinese Drugmaker Hengrui Soars in Hong Kong Trading Debut bloomberg.com/news/articles/…

Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion (while Blueprint was once focused on precision cancer therapies and still has an oncology pipeline, Sanofi's release has 0 mention of the cancer work) with Ashleigh Furlong Phoebe Sedgman bloomberg.com/news/articles/…

Bristol-Myers Squibb will pay BioNTech as much as $11.1 billion to license PD-L1/VEGF bispecific initially licensed from Chinese biotech Biotheus Naomi Kresge bloomberg.com/news/articles/…

More deals: Regeneron licenses GLP-1/GIP receptor agonist from Hansoh for $80 million upfront finance.yahoo.com/news/regeneron…

$AMGN gets one over on $ZLAB in DLL3. Via ApexOnco #ASCO25 oncologypipeline.com/apexonco/asco-…